|
PTCD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.96269692007445E-14 |
| Normal-vs-Stage2 |
4.22399999977507E-07 |
| Normal-vs-Stage3 |
7.90478793533111E-14 |
| Normal-vs-Stage4 |
2.14395168285364E-12 |
| Stage1-vs-Stage2 |
6.715200E-01 |
| Stage1-vs-Stage3 |
4.956000E-02 |
| Stage1-vs-Stage4 |
1.369860E-02 |
| Stage2-vs-Stage3 |
1.029020E-01 |
| Stage2-vs-Stage4 |
2.739800E-02 |
| Stage3-vs-Stage4 |
3.973000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.93529999997977E-06 |
| Normal-vs-Asian |
1.21919999995779E-06 |
| Caucasian-vs-AfricanAmerican |
5.320000E-01 |
| Caucasian-vs-Asian |
1.026800E-01 |
| AfricanAmerican-vs-Asian |
6.123200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.32431868091498E-13 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
7.455400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.24131824211327E-12 |
| Normal-vs-Age(41-60Yrs) |
4.36317648677687E-14 |
| Normal-vs-Age(61-80Yrs) |
2.51669796114129E-11 |
| Normal-vs-Age(81-100Yrs) |
9.50319999999394E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.648000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.681400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.488000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.074400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.728600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.826800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.003570E-02 |
| Classical-VS-Follicular |
6.955400E-01 |
| Classical-VS-Other |
4.458000E-01 |
| Classical-VS-Normal |
1.6269208202857E-12 |
| Tall-VS-Follicular |
1.125780E-02 |
| Tall-VS-Other |
5.849000E-01 |
| Tall-VS-Normal |
1.40800038295197E-10 |
| Follicular-VS-Other |
4.700800E-01 |
| Follicular-VS-Normal |
4.3334000054962E-08 |
| Other-VS-Normal |
1.084730E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.72861724934137E-13 |
| Normal-vs-N1 |
3.67630370590177E-11 |
| N0-vs-N1 |
2.056000E-01 |
|
|
